Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
December 04 2018 - 3:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One):
|
|
[ ]
Form 10-K
|
[ ]
Form 20-F
|
[ ]
Form 11-K
|
[X]
Form 10-Q
|
|
|
[ ]
Form 10-D
|
[ ]
Form N-SAR
|
[ ]
Form N-CSR
|
|
|
|
|
For
Period Ended:
|
September
30, 2018
|
|
|
|
|
[ ]
Transition Report on Form 10-K
|
|
|
[ ]
Transition Report on Form 20-F
|
|
|
[ ]
Transition Report on Form 11-K
|
|
|
[ ]
Transition Report on Form 10-Q
|
|
|
[ ]
Transition Report on Form N-SAR
|
|
|
For
the Transition Period Ended: __________________________________
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
Not
Applicable
PART
I—REGISTRANT INFORMATION
GENE
BIOTHERAPEUTICS INC.
(Full
Name of Registrant)
11568
Sorrento Valley Rd, Suite #14
San
Diego, California 92121
(Address
of Principal Executive Office)
PART
II—RULES 12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F,
Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion
thereof, will be filed on or before the fifth calendar day following the prescribed due
date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III—NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
The
Company requires additional time to finalize the annual report on Form 10-Q for the quarter ended September 30, 2018 within the
prescribed time to allow for additional time to make disclosures related to recent developments.
PART
IV—OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
Christopher
J. Reinhard
|
|
(858)
436-1000
|
(Name)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s). [ ] Yes [X] No
|
|
|
|
Form
10Q for the period ending June 30, 2017; Form 10Q for the period ending September 30, 2017; Form 10K for the period ending
December 31, 2017; Form 10Q for the period ending March 31, 2018; Form 10Q for the period June 30,2018
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No
|
|
|
|
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
GENE
BIOTHERAPEUTICS INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
December 4, 2018
|
By:
|
/s/
Christopher J. Reinhard
|
|
Name:
|
Christopher
J. Reinhard
|
|
Title:
|
Principal
Executive Financial and Accounting Officer
|
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From May 2024 to Jun 2024
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Jun 2023 to Jun 2024